WORCESTER, Mass.--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that the Company’s President and CEO, Tod Woolf, Ph.D., will deliver a session keynote presentation at IBC’s Oligonucleotide Therapeutics - From Concept to Creation Conference, which is part of Drug Discovery and Development Week, taking place August 3-6, 2009 in Boston, MA.
RNA interference (RNAi) technology has been heralded as a major breakthrough in science with the potential to block the expression of disease-causing genes. Dr. Woolf’s keynote “Thirty Years of Targeting RNA: A Retrospective” will explore the great variety of therapeutic oligonucleotide properties and how these characteristics provided insight on designing compounds with “self-delivery” properties, or delivery to cells and tissues without the use of a separate delivery vehicle. His presentation will begin at 9:10 am on Monday, August 3, 2009.
Dr. Woolf will also participate in a CEO panel discussion on RNA therapeutics that brings together leaders in the RNAi field to discuss the current and potential states of development, as well as how companies are capitalizing on the promise of this new class of drugs. The session will be held from 11:50 to 12:30 on Tuesday August 4, 2009. Furthermore, Dr. Woolf will serve as a panelist in a roundtable discussion on the intellectual property landscape in RNAi therapeutics at 4:15 on August 3, 2009.
In addition to the Keynote address and the CEO panel discussion by Dr. Woolf, the conference also includes a presentation by RXi’s Vice President of Technology Development, Dmitry Samarsky, Ph.D., on the “Development of Novel RNAi Therapeutic Compounds and In Vivo Delivery Approaches,” as well as a presentation by one of RXi’s collaborators, Gary Ostroff, Ph.D., using a technology platform licensed by RXi, the Glucan Encapsulated RNAi Particle (GeRP) delivery system.
IBC’s Drug Discovery and Development Week, to be held at the World Trade Center in Boston, MA, expects more than 3,000 pharmaceutical, biotechnology, government and academic researchers, executives, and technology providers to participate. The five targeted scientific conferences at this event focus on practical strategies and forward-looking approaches to help accelerate small molecules, antibody therapeutics and oligonucleotide therapeutics from early discovery to the clinic.
No comments:
Post a Comment